Presidio Pharmaceuticals, Inc, a specialty pharmaceutical company focused on developing and commercializing novel, small molecule compounds for the treatment of HIV-1, HCV and other chronic viral infections, has closed a $26 million Series B financing
Less
More
Tobira Therapeutics Inc., a newly established, clinical stage biotechnology company, today announced the completion of a $31 million Series A financing Tobira Therapeutics will focus on the clinical development of novel therapies for HIV/AIDS. The Company has entered into an exclusive license for technology and products developed by Takeda Pharmaceutical Company Limited of Osaka, […]
Panacos Pharmaceuticals: Hercules Provides $20 Million to Panacos Pharmaceuticals, Inc., a Biopharmaceutical Company Developing Novel Antiviral and HIV Therapies
Koronis Raises $20M in Series D Funding Koronis said the money will help pay for proof-of-concept studies for a prospective HIV treatment that employs a novel technology called Viral Decay Acceleration. Koronis said the treatment, called KP-1461, has already begun its Phase 2a trials and should finish its testing by some time next year.
Argos Therapeutics, which recently received a $21 million grant for HIV research, has raised $5 million in debt financing to help pay for ongoing clinical trials.
AlphaVax said Friday it has raised $12.7 million in its fifth funding round. AlphaVax has an AIDS vaccine in the first round of human trials. The company also recently received approval from the U.S. Food and Drug Administration to begin trials on vaccines for influenza and cytomegalovirus.
HIV
BioTechnology